logo
Plus   Neg
Share
Email

Zogenix Inc. (ZGNX) Has Soared To A New High On Phase 3 Study Results

Zogenix Inc. (ZGNX) announced Friday morning that its Phase 3 trial of ZX008, for the treatment of Dravet syndrome, met its primary objective and demonstrated statistically significant improvements versus placebo in all key secondary measures.

Zogenix has gapped open dramatically higher this morning and is now up 16.83 at $29.70 on the highest volume of the year. The stock has soared to a new high for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT